BARDA Archives - EverGlade Consulting

BARDA

BARDA Issues New RPP to Advance Smart Manufacturing for Antibodies

Leave a Comment / BARDA, Life Sciences / By

Driving Innovation in Antibody Manufacturing The Biomedical Advanced Research and Development Authority (BARDA) has launched a new Request for Project Proposals (RPP) aimed at transforming the speed, efficiency, and resilience of antibody (Ab) production. Issued under the Biopharmaceutical Manufacturing Preparedness Consortium (BioMaP-Consortium), the initiative seeks to integrate advanced manufacturing technologies into Ab production systems to […]

BARDA Issues New RPP to Advance Smart Manufacturing for Antibodies Read More »

BARDA’s mAb “Smart Manufacturing” Opportunity

Leave a Comment / BARDA, Life Sciences / By

Background The Biomedical Advanced Research and Development Authority (BARDA) within the Administration for Strategic Preparedness and Response (ASPR) has released a Draft Statement of Objectives (SOO) for feedback to help refine requirements for the upcoming “Smart Manufacturing” solicitation aiming to support the development of advanced monoclonal antibody (mAb) manufacturing and development techniques. The solicitation’s overarching

BARDA’s mAb “Smart Manufacturing” Opportunity Read More »

BARDA’s Onshoring of Viral Hemorrhagic Fevers Vaccine Candidates

Leave a Comment / BARDA, Life Sciences / By

As the global health landscape evolves, so too must the United States’ ability to respond rapidly to biological threats. To strengthen its readiness posture, the Biomedical Advanced Research and Development Authority (BARDA), in coordination with the Administration for Strategic Preparedness and Response (ASPR), has released a new opportunity under the BioMaP Consortium OT Vehicle. This

BARDA’s Onshoring of Viral Hemorrhagic Fevers Vaccine Candidates Read More »

Enzyme structure with biological concept 3d rendering

BARDA Solicits Enzymatic Debridement Solutions

Leave a Comment / All Posts, BARDA, Life Sciences / By

BARDA RFP – Enzymatic Debridement Products for Treatments of Deep and Full- Thickness Severe Burn Injuries – 75A50125R00007 – Amendment 0001 The Biomedical Advanced Research and Development Authority (BARDA), a division of the U.S. Department of Health and Human Services (HHS), has released a significant new opportunity to strengthen national preparedness for burn mass casualty

BARDA Solicits Enzymatic Debridement Solutions Read More »

Biothreat Pathogens

BARDA Launches RFP for vaccines targeting Marburg virus (MARV) and Sudan ebolavirus (SUDV)

Leave a Comment / BARDA, Life Sciences / By

BARDA RFP – Marburg Virus and Sudan Ebolavirus Vaccine Licensure and Procurement On July 12, 2025, the Biomedical Advanced Research and Development Authority (BARDA) issued Request for Proposals (RFP) #75A50125R00006. This RFP seeks proposals for the advanced development, FDA licensure, and procurement of vaccines targeting Marburg virus (MARV) and Sudan ebolavirus (SUDV). With recent outbreaks

BARDA Launches RFP for vaccines targeting Marburg virus (MARV) and Sudan ebolavirus (SUDV) Read More »

Close up of blue antibiotic capsules

BARDA Launches New RFP to Bolster Antibiotic Stockpiles Against Drug-Resistant and Biothreat Pathogens

Leave a Comment / BARDA, Life Sciences / By

Request for Proposals (RFP) for Antibiotic for Treatment of Bacterial Pneumonia or Bloodstream Infections Bolstering Biodefense with Advanced Antibiotics: BARDA’s Strategic Move As the threat of antibiotic-resistant infections intensifies, the U.S. Department of Health and Human Services (HHS), through the Biomedical Advanced Research and Development Authority (BARDA), has issued a pivotal solicitation under Project BioShield

BARDA Launches New RFP to Bolster Antibiotic Stockpiles Against Drug-Resistant and Biothreat Pathogens Read More »

enzymatic debridement product

BARDAs Strategic Investment in Enzymatic Debridement Products

Leave a Comment / BARDA, Life Sciences / By

Advancing Burn Care Preparedness: BARDA’s Strategic Investment in Enzymatic Debridement Products In its ongoing mission to strengthen the nation’s biodefense and emergency response infrastructure, the Biomedical Advanced Research and Development Authority (BARDA), an office within the Administration for Strategic Preparedness and Response (ASPR) at the U.S. Department of Health and Human Services, has released a

BARDAs Strategic Investment in Enzymatic Debridement Products Read More »

Transparent ampules on a blue background

BARDA’s Call to Action Antibiotics for Treatment of Bacterial Pneumonia or Bloodstream Infections

Leave a Comment / All Posts, BARDA, Life Sciences / By

Combating Resistant Infections: BARDA’s Push for Advanced Antibiotics The Biomedical Advanced Research and Development Authority (BARDA), part of the U.S. Department of Health and Human Services (HHS), has released a pre-solicitation notice aimed at identifying qualified vendors to support the late-stage development, procurement, and stockpiling of antibiotics for critical public health threats. Targeted programs include

BARDA’s Call to Action Antibiotics for Treatment of Bacterial Pneumonia or Bloodstream Infections Read More »

Vaccine Development

BARDA’s Call to Action on Marburg and Sudan Virus Vaccines

Leave a Comment / BARDA, Life Sciences / By

Preparing for the Next Biological Threat: BARDA’s Vaccine Initiative for MARV and SUDV The Biomedical Advanced Research and Development Authority (BARDA), operating under the U.S. Department of Health and Human Services (HHS), has issued a pre-solicitation notice signaling its intent to launch a major Request for Proposal (RFP) later this year. This effort, managed by

BARDA’s Call to Action on Marburg and Sudan Virus Vaccines Read More »

Vaccine Research

Strengthening National Preparedness: BARDA’s FY23 Modernized BAA

Leave a Comment / BARDA, Life Sciences / By

Strengthening National Preparedness: BARDA’s FY23 Modernized BAA BAA-23-100-SOL-00004 – Office of Biomedical Advanced Research and Development Authority (BARDA) Broad Agency Announcement (BAA) In response to today’s evolving public health landscape, the Biomedical Advanced Research and Development Authority (BARDA), a division of the U.S. Department of Health and Human Services (HHS) within the Administration for Strategic

Strengthening National Preparedness: BARDA’s FY23 Modernized BAA Read More »

Rapid Response Test

BARDA’s DxR2 RPP: Scaling Biothreat Diagnostic Readiness

Leave a Comment / All Posts, BARDA, Life Sciences / By

In a continued effort to bolster national preparedness against emerging biological threats, the Biomedical Advanced Research and Development Authority (BARDA) has released the Phase 2 issue of the “Biothreat Diagnostic Rapid Response” Solicitation (RPP-25-06-DxR2) on May 29, 2025, under its Rapid Response Partnership Vehicle (RRPV). BARDA is seeking to address pressing gaps in diagnostic test

BARDA’s DxR2 RPP: Scaling Biothreat Diagnostic Readiness Read More »

The White House Initiatives

White House Unveils New Initiatives for Critical Medicines and Biological Research Safety

Leave a Comment / All Posts, ARPA-H, BARDA, Life Sciences / By

Promoting Domestic Production of Critical Medicines The White House is pushing to see more state-of-the-art pharmaceutical manufacturing facilities within the United States to strengthen the supply of essential medicines. On May 5, 2025, the President signed an Executive Order titled “Regulatory Relief to Promote Domestic Production of Critical Medicines.” The goal of this order is

White House Unveils New Initiatives for Critical Medicines and Biological Research Safety Read More »

Scroll to Top